Synopsis-
“On Tuesday, the drug manufacturing company, Novo Nordisk, said its blockbuster obesity drug Wegovy is capable of reducing the risk of cardiovascular events.”
Study says, obesity drugs bring heart health advantages alongside weight loss. This finding has been found remarkable in medical history as one medication will be effective against two diseases.
On Tuesday, the drug manufacturing company, Novo Nordisk, said its blockbuster obesity drug Wegovy is capable of reducing the risk of cardiovascular events.
This study is groundbreaking in showing that a medication designed for weight loss can provide additional medical benefits beyond simply weight loss.
Wegovy has been trending for several reasons-
As said, the popular obesity drug, Wegovy has been in the news for several reasons, and one of them is getting insurance coverage for patients. It has been difficult for many individuals who use Wegovy to get insurance coverage for the weekly injections, which can cost over $1,300 per month. This is because the medication is sometimes viewed as a treatment for lifestyle rather than a medical necessity.
Dr. Shauna Levy, a specialist in obesity medicine and the medical director of the Tulane Bariatric Center in New Orleans, said, “The results may be compelling enough to get insurance companies to provide coverage. Twenty percent is huge. All of this narrative about people just wanting this for cosmetic reasons, I think, to some degree, has overshadowed all of the health benefits we can get from this medication.”
What Novo Nordisk Said about the Drug?
According to Novo Nordisk, the drug showed no signs of adverse effects and was well received, consistent with the results of previous clinical trials.
The results were derived from a clinical trial conducted on over 17,000 adults aged 45 and above. These individuals were administered a 2.4-milligram dose of Wegovy or a placebo in addition to standard care.
